Phase 2 trial links early monocyte elevation to response in gastric cancer immunotherapy
Small study finds immune cell changes linked to better response in gastric cancer treatment
A phase 2 trial in 24 patients with metastatic gastric cancer receiving first-line pembrolizumab plus XELOX found that early elevation of ci…
Patients with metastatic gastric cancer who saw early immune cell changes in their blood were more likely to survive longer while receiving …
pCR shows poor surrogacy for OS in neoadjuvant GEA trials overall, but strong for esophageal adenocarcinoma
When a cancer disappears before surgery, does it mean patients live longer? Not always, a major review finds.
A meta-analysis of 26 RCTs (n=7452) found pathologic complete response (pCR) was not a valid surrogate for overall survival (OS) in neoadjuv…
For stomach or esophageal cancer, a tumor disappearing before surgery does not always mean patients live longer, a major review finds.